The biologic window for chimeric l6 radioimmunotherapy
| Autor: | Ingegerd Hellstrom, R B A Gary Mirick, Gerald L. DeNardo, Karl Erik Hellstrom, Sally J. DeNardo, Linda A. Kroger, Lois F. O'Grady, Aina Yuan, Kent L. Erickson, Kathleen R. Lamborn |
|---|---|
| Rok vydání: | 1994 |
| Předmět: |
Cancer Research
Pathology medicine.medical_specialty medicine.drug_class business.industry medicine.medical_treatment Ovary medicine.disease Monoclonal antibody Peripheral blood mononuclear cell In vitro Cytolysis medicine.anatomical_structure Oncology Antigen Radioimmunotherapy medicine Adenocarcinoma business |
| Zdroj: | Cancer. 73:1023-1032 |
| ISSN: | 1097-0142 0008-543X |
| DOI: | 10.1002/1097-0142(19940201)73:3+<1023::aid-cncr2820731341>3.0.co;2-u |
| Popis: | Background. There has been little success in using radioimmunotherapy in patients with adenocarcinoma, partly because of the low tumor uptake of the administered monoclonal antibody (MoAb). The authors recently reported therapeutic response in advanced cancer patients who received 131 I chimeric-L6 MoAb. The L6 MoAb identifies abundant, nonshed antigen that is expressed in many human carcinomas, including carcinomas of the lung, breast, colon, and ovary. In vitro both mouse L6 (L6) and chimeric L6 (ChL6) mediate complement-dependent tumor cytolysis with human serum, and antibody-dependent tumor cell cytolysis with normal human peripheral blood mononuclear cells |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text